若不治疗耐多药结核病的危险。
The risk of leaving multidrug-resistant tuberculosis untreated.
预防和控制耐多药结核病和广泛耐药结核病。
Prevention and control of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis.
7月，卫生工作者治疗第一批耐多药结核病患者。
By July, health workers were treating the first MDR-TB patients.
2007年，耐多药结核病例估计数为50万例。
There were an estimated 0.5 million cases of multidrug-resistant TB (MDR-TB) in 2007.
在2006年，估计有50万例耐多药结核病例。
There were an estimated 0.5 million cases of multidrug-resistant TB (MDR-TB) in 2006.
问：你对与耐多药结核病作斗争的前途有什么看法？
开发抗击耐多药/广泛耐药结核病所需要的新工具。
对普通结核病的不规范治疗致使耐多药菌株滋生繁殖。
Substandard treatment of normal TB drives the development of multi-drug resistant strains.
在研究的544名患者中，有221人患有耐多药结核。
这相当于痰涂阳性的耐多药结核病例全球估计总数的1%。
This is equivalent to 1% of the estimated global total of smear-positive cases of MDR-TB.
在美国，4%的耐多药结核病例符合广泛耐药结核的标准。
In the United States, 4% of MDR-TB cases met the criteria for XDR-TB.
耐多药结核病是一种对一线标准药物没有反应的结核病形式。
MDR-TB is a form of TB that fails to respond to standard first-line drugs.
估计全世界将近50%的耐多药结核病例发生在中国和印度。
Almost 50% of MDR-TB cases worldwide are estimated to occur in China and India.
结核病规划在减少耐多药结核病发病率方面面临着巨大挑战。
Tuberculosis programmes face tremendous challenges in reducing MDR-TB rates.
这仅相当于痰涂阳性耐多药结核病例全球估计总数的8.5%。
This was 8.5% of the estimated global total of smear-positive cases of MDR-TB.
确保制定一个耐多药/广泛耐药结核病综合管理与治疗框架；
to ensure development of a comprehensive M/XDR-TB management and care framework;
问：除了钱外，什么是开展耐多药结核病治疗规划的最重要因素？
Q: Aside from money, what has been the most important factor in running a MDR-TB treatment programme?
结核病控制在稳步取得进步，但耐多药结核病却达到了历史较高水平。
Progress in tuberculosis control remains steady but multi-drug resistant TB has reached historic levels.
6个月疗程结束后的仅数月内，他再次病倒，这次是耐多药结核病。
Only a few months after finishing his six-month treatment, Gagarin became sick again – this time with MDR-TB.
用二线药物治疗耐多药结核所需时间更长，更加昂贵，并且产生更多副作用。
MDR-TB takes longer to treat with second-line drugs, which are more expensive and have more side-effects.
形成耐多药结核或广泛耐药结核的第二个途径是患者自身的结核产生耐药性。
A second way of developing MDR-TB or XDR-TB is when a patient's own TB develops resistance.
耐多药结核病的蔓延引起了人们的特别关注，尤其是在东欧、中亚部分和中国。
The spread of multi-drug resistant TB is a cause of particular concern, especially in Eastern Europe, parts of Central Asia, and China.
在许多国家，艾滋病毒加快了结核病流行，同时多药耐药性也日益成为一大威胁。
HIV is fuelling TB epidemics in many countries and multi-drug resistance is a growing threat.
在治疗耐多药结核的二线药物被滥用的任何地方，存在着广泛耐药结核的可能性。
Wherever second-line drugs to treat MDR-TB are being misused, the possibility of XDR-TB exists.
世卫组织今年早些时候发布的一个报告表明，耐多药结核病发病率已达到记录新高。
Earlier this year, WHO issued a report showing that multi-drug resistant TB has reached the highest levels ever recorded.
为了支持北京会议的目标，帮助各国扩展耐多药结核病控制的计划工具正在开发中。
In support of the Beijing meeting's aims, planning tools are being developed to help countries scale up their MDR-TB control efforts.
各国预计将接受治疗的耐多药结核病例总数在2007和2008年各为约5万人。
The total number of MDR-TB cases that countries forecast will be enrolled on treatment in 2007 and 2008 is about 50 000 in both years.
然而，还需要进行更多研究才能确定耐多药结核病和艾滋病在全球的流行是否有重叠。
However, more research is needed to determine whether there is an overlap between the MDR-TB and HIV epidemics worldwide.
然而，还需要进行更多研究才能确定耐多药结核病和艾滋病在全球的流行是否有重叠。
However, more research is needed to determine whether there is an overlap between the MDR-TB and HIV epidemics worldwide.
应用推荐